This week on Eye on the Cure, Dr. Lenore von Krusenstiern of BlueRock Therapeutics joins host Ben Shaberman to discuss an exciting new clinical trial for photoreceptor replacement therapy targeting inherited retinal conditions like retinitis pigmentosa and cone-rod dystrophy. Using induced pluripotent stem cells, this groundbreaking approach—developed in the lab of stem cell pioneer Dr. David Gamm—aims to restore vision by replacing lost photoreceptors. Listen now to learn more about this innovative therapy: https://bit.ly/4msStrW Image Description: Dark blue background with Foundation Fighting Blindness logo in the top left and Eye on the Cure Podcast logo in the top right. Teal half circle at the top center with "Ep. 86" inside. Below, text reads, "Listen to the latest podcast episode out now. May 23, 2025." To the left is Ben Shaberman with "Ben Shaberman, Host" beneath. To the right is Dr. Lenore von Krusenstiern with "Dr. Lenore von Krusenstiern, Guest" below. (fb)

Spotlight on PRPH2 👁️‍🗨️ To date, researchers have identified more than 200 different mutations in PRPH2 linked to inherited retinal disease. Each discovery brings us closer to understanding—and treating—these conditions. Learn more on our website at www.FightingBlindness.org/diseases/prph2 Image Description: Dark blue background with the Foundation Fighting Blindness and “Spotlight on PRPH2” logos in the top left corner. Text below reads, "Researchers have identified more than 200 different mutations in PRPH2 linked to inherited retinal disease." A blue strand of DNA breaking in half across the bottom. (fb)